Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a new study.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.
Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of Stevens-Johnson syndrome or toxic epidermal necrolysis between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.
Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of Stevens-Johnson syndrome or toxic epidermal necrolysis. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.
“In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed recurrence risk in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …” the authors write.
“… these findings are relevant to physicians who care for patients with a history of SJS or TEN. Because most such episodes are drug-induced, the high risk of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions.”
Citation: Yaron Finkelstein MD, ABCP(Dip), Erin M. Macdonald MSc, Ping Li PhD, Janine R. Hutson MD, MSc, David N. Juurlink MD, PhD, 'Recurrence and Mortality Following Severe Cutaneous Adverse Reactions', JAMA. 2014;311(21):2231-2232. doi:10.1001/jama.2014.839
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Is That A Real Patient Or A Junkie? Now There's An App For That
- How The Higgs Became The Target Of Run 2 At The Tevatron
- You Are Ready To Eat Insects If You Have These Characteristics
- Global 'Roadmap' Shows Where To Put Roads Without Costing The Earth
- How Neuroscience Is Being Used To Spread Quackery In Business And Education
- MOOCs: Learning About Online Learning, One Click At A Time
- Will We Meet ET Microbes On Mars? Why We Should Care Deeply About Them - Like Tigers
- "More precisely: you can say that you have a quantum of an EM wave *after* one combined creation/detection..."
- "What are you planning to do this Month? Here is the list of 200 free online courses that start..."
- "So in this representation every four vector is represented by a 4x4 matrix, but not every 4x4 matrix..."
- "If you look up a text on Quantum Electrodynamics you should find a Psi field for creating and destroying..."
- "You guessed alright, that is a page from the book...Cheers,T...."
- Geochronology and global context of the Charnian Supergroup
- Confirmation of a low pre-extensional geothermal gradient in the Grayback normal
- Scientists get set for simulated nuclear inspection
- Invisible blood in urine may indicate bladder cancer
- Sugar substance 'kills' good HDL cholesterol, new research finds